Actively Recruiting
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
Led by Massachusetts General Hospital · Updated on 2026-04-20
30
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
B
Boehringer Ingelheim
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.
CONDITIONS
Official Title
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 40 years
- Ability to provide written informed consent
- First degree relative of a family member with pulmonary fibrosis (Group 1)
- No known history of interstitial lung disease (Group 1)
- No tobacco use within the prior 6 months (Group 1)
- Interstitial lung abnormalities or early interstitial lung disease defined by reticular markings and/or traction bronchiectasis without definite UIP pattern (Group 2)
- No tobacco use within the prior 6 months (Group 2)
You will not qualify if you...
- Presence of electrical implants such as cardiac pacemaker or perfusion pump
- Presence of ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants
- Historical estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2
- Pregnant or breastfeeding females (negative serum hCG pregnancy test required before participation)
- Claustrophobic reactions
- Research-related radiation exposure exceeding 50 mSv in the prior 12 months
- Unable to lie comfortably inside the MR-PET scanner
- Body mass index (BMI) over 33
- Clinically unsuitable as determined by investigators
- Pneumonia or other acute respiratory illness within 6 weeks prior to study entry
- Parenchymal lung disease other than ILD, ILAs, or emphysema
- Acute exacerbation of ILD within the prior 6 months
- Video-assisted thoracoscopic surgery (VATS) within the prior 6 months
- Prior radiation therapy to the thorax
- Known allergy to gadolinium contrast agent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
Research Team
S
Sydney B Montesi, MD
CONTACT
A
Abimbola Akinniyi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here